Appointment dossier — Prostate Adenocarcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Prostate Adenocarcinoma
- Cisplatin — Review evidence · 1 positive / 1 negative-mixed · PMID 33413292, 18408396
- Docetaxel — Review evidence · 1 positive · PMID 33413292
- Etoposide — Review evidence · 1 positive / 1 negative-mixed · PMID 33413292, 37485216, 18408396
- Carboplatin — Review evidence · 0 positive · PMID 37485216
- Durvalumab — Review evidence · 0 positive · PMID 37485216
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06236139 · Phase 1 / Phase 2 — Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (United States)
- NCT04734730 · Phase 2 — Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer (United States)
- NCT06499870 · Phase 2 — Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial (United States)
- NCT06022822 · Phase 2 — Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial (United States)
- NCT05691465 · Phase 2 — Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells (United States)
- NCT07641049 · Phase 1 — Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer (China)
- NCT06813898 · Early Phase 1 — An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial (United States)
- NCT04945642 — High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma (United States)
- NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
- NCT07145255 · Phase 1 / Phase 2 — Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors (United States)
- NCT07288359 · Phase 1 / Phase 2 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (United States)
- NCT06942104 · Phase 1 — Imaging of Solid Tumors Using 18F-TRX (United States)
- NCT07006727 · Phase 1 — Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors (United States)
- NCT05932862 · Phase 1 — A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors (United States)
- NCT06389097 — SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization (United States)
- NCT06099093 · Phase 4 — Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan (United States)
- NCT03678025 · Phase 3 — Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer (United States)
- NCT01492972 · Phase 3 — Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer (United States)
Most-relevant first: trials that name Prostate Adenocarcinoma, then broader trials you may still qualify for. 184 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06236139), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?